Indeed, with the increasing use of PD-1 or PD-L1 inhibitors in cancer immunotherapy, autoimmune thyroid diseases have been frequently described, with thyroiditis (38%) reported as the most common first irAEs in patients receiving anti-PD-L1 immunotherapy [19]. This evidence concerns the gene PDCD1 and autoimmune thyroid disease.